Published in

Elsevier, Annals of Oncology, 3(25), p. 599-605, 2014

DOI: 10.1093/annonc/mdt588

Links

Tools

Export citation

Search in Google Scholar

A randomized phase III study comparing pegylated liposomal doxorubicin with capecitabine as first-line chemotherapy in elderly patients with metastatic breast cancer: results of the OMEGA study of the Dutch Breast Cancer Research Group BOOG†

Journal article published in 2014 by C. H. Smorenburg, S. M. de Groot, A. E. van Leeuwen-Stok, M. E. Hamaker, A. N. Wymenga, H. de Graaf, F. E. de Jongh, J. J. Braun, M. Los, E. Maartense, H. van Tinteren ORCID, J. W. R. Nortier, C. Seynaeve
This paper is available in a repository.
This paper is available in a repository.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

In a prospective randomized clinical trial in elderly patients with metastatic breast cancer, pegylated liposomal doxorubicin and capecitabine demonstrated comparable efficacy and acceptable tolerance as first-line single-agent chemotherapy.